Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS.
Clin Cancer Res. 2012 Mar 15;18(6):1641-54. Epub 2012 Jan 24.
Related citations
DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, Iniguez L, Soriano R, Huw L, Stern H, Modrusan Z, Seshagiri S, Hampton GM, Amler LC, Bourgon R, Yauch RL, Shames DS.
Clin Cancer Res. 2012 Apr 15;18(8):2360-73. Epub 2012 Jan 19.
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH, Cho BC.
Clin Cancer Res. 2012 Mar 15;18(6):1760-8. Epub 2012 Jan 23.
Genetic variations in epigenetic genes are predictors of recurrence in stage I or II non-small cell lung cancer patients.
Wagner KW, Ye Y, Lin J, Vaporciyan AA, Roth JA, Wu X.
Clin Cancer Res. 2012 Jan 15;18(2):585-92.
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.
Clin Cancer Res. 2012 Mar 1;18(5):1472-82. Epub 2012 Jan 10.
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM.
Clin Cancer Res. 2012 Feb 15;18(4):1138-45. Epub 2012 Jan 6.
Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis.
Valencia K, Ormazábal C, Zandueta C, Luis-Ravelo D, Antón I, Pajares MJ, Agorreta J, Montuenga LM, Martínez-Canarias S, Leitinger B, Lecanda F.
Clin Cancer Res. 2012 Feb 15;18(4):969-80. Epub 2012 Jan 5.
Prognostic immune markers in non-small cell lung cancer--letter.
Pandey JP.
Clin Cancer Res. 2011 Dec 15;17(24):7835; author reply 7836. Epub 2011 Dec 6. No abstract available.
Error occurred: cannot get document summary
Using patient-initiated study participation in the development of evidence for personalized cancer therapy.
Ambrose LF, Freedman J, Buetow K, Friend S, Schilsky RL.
Clin Cancer Res. 2011 Nov 1;17(21):6651-7.
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S.
Clin Cancer Res. 2011 Nov 1;17(21):6847-57. Epub 2011 Sep 14.
Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.
Masuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.
Clin Cancer Res. 2011 Dec 15;17(24):7712-22. Epub 2011 Oct 20.
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, Gustavson M, Ranger-Moore J, Gaire F, Matsubayashi J, Nagao T, Yoshida K, Ohira T, Ikeda N, Hirsch FR.
Clin Cancer Res. 2011 Dec 15;17(24):7796-807. Epub 2011 Oct 12.
Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system.
Kossenkov AV, Vachani A, Chang C, Nichols C, Billouin S, Horng W, Rom WN, Albelda SM, Showe MK, Showe LC.
Clin Cancer Res. 2011 Sep 15;17(18):5867-77. Epub 2011 Aug 1.
A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis.
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J.
Clin Cancer Res. 2011 Nov 1;17(21):6802-11. Epub 2011 Sep 2.
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ.
Clin Cancer Res. 2011 Oct 1;17(19):6298-303. Epub 2011 Aug 19.
Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer.
Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.
Clin Cancer Res. 2011 Oct 1;17(19):6272-86. Epub 2011 Aug 17.
Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.
Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR.
Clin Cancer Res. 2011 Oct 1;17(19):6206-17. Epub 2011 Aug 15.
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA.
Clin Cancer Res. 2011 Oct 1;17(19):6322-8. Epub 2011 Aug 10.
Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer.
Aragaki M, Takahashi K, Akiyama H, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y.
Clin Cancer Res. 2011 Sep 15;17(18):5889-900. Epub 2011 Aug 3.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on